BIBA Publishing

The product received US Food and Drug Administration 510(k) clearance in February 2016. It is intended for use in neonates and infants for repair of pericardial structures, as an epicardial covering for damaged or repaired cardiac structures, as a patch material for intracardiac defects, septal defects and annulus repair, suture-line buttressing, and cardiac repair.

The first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn, USA. This AtriCure-sponsored trial will evaluate intraoperative cryoanalgesia therapy using cryoablation in conjunction with standard of care (SOC) pain management compared to SOC alone.